IOVA vs MESO: fair value comparison
Iovance Biotherapeutics, Inc. and Mesoblast Limited · Updated 2026-10-19
IOVA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MESO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, IOVA currently ranks higher by quality score.
| IOVA | MESO | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $13.62 | $13.28 |
| 12-month range | $1.81–$14.82 | $13.19–$20.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #103 of 301 Healthcare | #105 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: IOVA fair value analysis · MESO fair value analysis